title: EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.
abstract: BACKGROUND
  We assessed the effect of zoledronic acid on quality of life (QOL) and pain outcome in breast cancer patients with bone metastases using the European Organization for Research and Treatment of Cancer bone metastases module (EORTC QLQ-BM22).
  
  
  METHODS
  Three hundred sixty-six breast cancer patients receiving zoledronic acid for bone metastases from 13 Centers were prospectively enrolled. QOL was evaluated using the EORTC QLQ-BM22 and pain outcome were measured monthly with a Visual Analog Scale (VAS) score for 24 months.
  
  
  RESULTS
  No significant change of functional scale (functional interference and psychosocial aspects) of the EORTC QLQ-BM22 was reported. Significant reduction of the symptom scale was noted after treatment compared with the baseline. The painful site subscale was significantly reduced during the first 12 months, with the exception the 6-month follow-up of point. Pain characteristics subscale was also significantly lower from the 2-month time point onwards. VAS scores indicated a significant reduction in pain over the course of the study to the 22-month time point follow-up compared to the baseline.
  
  
  CONCLUSIONS
  Zoledronic acid treatment improved QOL of breast cancer patients with bone metastases by relieving bone pain.
authors.affiliation: Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Dah-Cherng
authors.initials: DC
authors.lastname: Yeh
authors.affiliation: Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan, R.O.C.
authors.forename: Dar-Ren
authors.initials: DR
authors.lastname: Chen
authors.affiliation: Department of Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, R.O.C.
authors.forename: Tsu-Yi
authors.initials: TY
authors.lastname: Chao
authors.affiliation: Department of Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
authors.forename: Shin-Cheh
authors.initials: SC
authors.lastname: Chen
authors.affiliation: Department of Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Hwei-Chung
authors.initials: HC
authors.lastname: Wang
authors.affiliation: Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, R.O.C.
authors.forename: Kun-Ming
authors.initials: KM
authors.lastname: Rau
authors.affiliation: Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan, R.O.C.
authors.forename: Yin-Hsun
authors.initials: YH
authors.lastname: Feng
authors.affiliation: Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan, R.O.C.
authors.forename: Yuan-Ching
authors.initials: YC
authors.lastname: Chang
authors.affiliation: Department of Hematology and Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan, R.O.C.
authors.forename: Kuan-Der
authors.initials: KD
authors.lastname: Lee
authors.affiliation: Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, R.O.C.
authors.forename: Fu
authors.initials: F
authors.lastname: Ou-Yang
authors.affiliation: Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
authors.forename: Wen-Hung
authors.initials: WH
authors.lastname: Kuo
authors.affiliation: Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Surgery, Cheng Ching General Hospital, Taichung, Taiwan, R.O.C.
authors.forename: King-Jen
authors.initials: KJ
authors.lastname: Chang
authors.affiliation: Department of Medicine, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan, R.O.C.
authors.forename: Yung-Chang
authors.initials: YC
authors.lastname: Lin
authors.affiliation: Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C. School of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C. lmtseng@vghtpe.gov.tw.
authors.forename: Ling-Ming
authors.initials: LM
authors.lastname: Tseng
authors.affiliation: Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, R.O.C. Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan, R.O.C.
authors.forename: Ming-Feng
authors.initials: MF
authors.lastname: Hou
mesh_terms: D000328:Adult; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary*; D001943:Breast Neoplasms / Q000150:complications / Q000473:pathology*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008875:Middle Aged; D010146:Pain / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D059408:Pain Management; D010147:Pain Measurement; D011788:Quality of Life; D013997:Time Factors; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid
keywords: Zoledronic acid; bone metastases; breast cancer; pain; quality of life